API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercebiotech.com/biotech/miratis-long-wait-next-lung-cancer-med-ends-phase-3-failure
https://ir.mirati.com/press-releases/press-release-details/2023/Mirati-Therapeutics-Provides-Update-on-the-Phase-3-SAPPHIRE-Study-Evaluating-Sitravatinib-in-Combination-with-OPDIVO/default.aspx
https://www.fiercebiotech.com/biotech/miratis-sitravatinib-yet-improve-survival-interim-phase-3-cancer-review-pushing-back
https://www.biospace.com/article/releases/mirati-therapeutics-presents-phase-2-data-on-sitravatinib-in-combination-with-nivolumab-in-urothelial-cancer-at-esmo-virtual-congress/
https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-initial-data-in-renal-cell-carcinoma-from-ongoing-investigator-sponsored-clinical-trial-of-sitravatinib-in-combination-with-nivolumab-at-the-2020-asco-genitourinary-cancers-syposium-301005654.html
https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-presentation-of-interim-phase-2-sitravatinib-data-in-urothelial-carcinoma-and-oral-cavity-squamous-cell-carcinoma-at-the-sitc-34th-annual-meeting-300944341.html
https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-first-patient-dosed-in-phase-1b-clinical-trial-of-sitravatinib-in-combination-with-anti-pd1-antibody-tislelizumab-in-patients-with-advanced-solid-tumors-300747130.html
https://www.prnewswire.com/news-releases/mirati-presents-preliminary-biomarker-data-from-ongoing-phase-2-clinical-trial-of-sitravatinib-in-combination-with-nivolumab-at-the-sitc-33rd-annual-meeting-300747376.html